Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Not Confirmed
Not Confirmed
12-14 January, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 February, 2026
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Biotech ShowcaseBiotech Showcase
Industry Trade Show
Not Confirmed
12-14 January, 2026
Digital content

11 Dec 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251211085624/en/Avenzo-Therapeutics-Presents-Initial-Results-from-the-Phase-12-Study-of-AVZO-021-a-Potential-Best-in-Class-CDK2-Inhibitor-at-the-2025-San-Antonio-Breast-Cancer-Symposium

24 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251124173033/en/Avenzo-Therapeutics-Granted-Fast-Track-Designation-for-AVZO-103-a-Potential-Best-in-Class-Nectin4TROP2-Bispecific-Antibody-Drug-Conjugate-for-the-Treatment-of-Patients-with-Urothelial-Cancer-Previously-Treated-with-Enfortumab-Vedotin

19 Nov 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251119935505/en/Avenzo-Therapeutics-Announces-Appointment-of-Scott-Lipman-as-Chief-Financial-Officer

10 Nov 2025
// BUSINESS WIRE
https://www.businesswire.com/news/home/20251110260582/en/Avenzo-Therapeutics-Granted-Fast-Track-Designation-for-AVZO-1418-a-Potential-Best-in-Class-EGFRHER3-Bispecific-Antibody-Drug-Conjugate-for-the-Treatment-of-Patients-with-EGFR-Mutated-TKI-Pretreated-NSCLC

30 Oct 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20251030143206/en/Avenzo-Therapeutics-to-Present-Initial-Results-from-the-Phase-1-Study-of-AVZO-021-a-Potential-Best-in-Class-CDK2-Inhibitor-at-the-2025-San-Antonio-Breast-Cancer-Symposium

29 Sep 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250929211412/en/Avenzo-Therapeutics-Initiates-Phase-12-Clinical-Study-of-AVZO-103-a-Potential-Best-in-Class-Nectin4TROP2-Bispecific-Antibody-Drug-Conjugate
ABOUT THIS PAGE